Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVX101
- Development stage
- Unknown
- Lead developer
- NeoVascularX
- Administration
- Topical, Ophthalmic
01
Overview
NVX101 (also known as AMD101) is a topical ophthalmic formulation being developed by NeoVascularX for the treatment of age-related macular degeneration (AMD). Originally licensed from AMD Therapeutics, the drug is designed to deliver therapeutic agents to the sub-retinal tissue via topical eye drops, providing a non-invasive alternative to standard intravitreal injections. While the specific molecular target has not been disclosed by the developer, the product is engineered for high stability and efficient posterior segment penetration. It is currently in Phase 1/2 clinical development.
- Other names
- AMD101 Topical Ophthalmic ProductAMD-101 Topical Ophthalmic ProductAMD 101 Topical Ophthalmic Product
Beyond the preview
Go deeper on NVX101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVX101.